Track market-moving stories before they get noisy

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Cronos Group (CRON - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Cronos Group is a member of our Medical group, which includes 920 different companies and currently sits at #9 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Cronos Group is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for CRON's full-year earnings has moved 175% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the latest available data, CRON has gained about 28.5% so far this year. Meanwhile, the Medical sector has returned an average of 3.5% on a year-to-date basis. This shows that Cronos Group is outperforming its peers so far this year.

Curaleaf Holdings, Inc. (CURLF - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 29.4%.

For Curaleaf Holdings, Inc., the consensus EPS estimate for the current year has increased 103.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

To break things down more, Cronos Group belongs to the Medical - Drugs industry, a group that includes 139 individual companies and currently sits at #154 in the Zacks Industry Rank.

In contrast, Curaleaf Holdings, Inc. falls under the Medical - Products industry. Currently, this industry has 86 stocks and is ranked #97.

Investors interested in the Medical sector may want to keep a close eye on Cronos Group and Curaleaf Holdings, Inc. as they attempt to continue their solid performance.

Cronos Group (CRON - Free Report) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.

The upward trend in estimate revisions for this cannabis company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Cronos Group, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsThe earnings estimate of $0.03 per share for the current quarter represents a change of -57.1% from the number reported a year ago.

The Zacks Consensus Estimate for Cronos has increased 200% over the last 30 days, as one estimate has gone higher compared to no negative revisions.

Current-Year Estimate RevisionsFor the full year, the company is expected to earn $0.20 per share, representing a year-over-year change of +1,100.0%.

There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, one estimate has moved up for Cronos versus no negative revisions. This has pushed the consensus estimate 175% higher.

Favorable Zacks RankOur research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineWhile strong estimate revisions for Cronos have attracted decent investments and pushed the stock 12.5% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.

3.6K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Cannabis: One Stock to Play the MovementCronos Group NASDAQ: CRON reported record second-quarter net revenue, gross profit and adjusted EBITDA for 2026, supported by growth in Israel, Canada and other international markets, including Germany.

Consolidated net revenue rose 58% year over year to $53 million, while gross profit increased 96% to $28.5 million. Adjusted EBITDA reached a record $13.1 million, improving by $11.4 million from the prior-year period.

Get Cronos Group alerts:

Will This New Development Mean A Big Rally In Cannabis Stocks?Chairman, President and CEO Mike Gorenstein said the results reflected momentum behind the company’s “borderless product strategy” across its operating regions. CFO Anna Shlimak said higher cannabis flower sales in Israel, Canada and Germany, as well as increased Canadian cannabis extract sales, drove revenue growth.

Margin gains supported by mix, volumes and growing conditions Shlimak said gross-profit growth was driven by higher average selling prices, sales mix shifting toward Israel and other international markets that do not carry excise taxes, and higher volumes that improved overhead-cost absorption. She also pointed to seasonally favorable growing conditions, which contributed to higher yields and more Grade A flower available for sale.

Cronos Group Inc's Revenues Are Up, Is It Time to Buy?“This quarter’s gross margin demonstrates what our business looks like when it’s firing on all cylinders,” Shlimak said, while cautioning that quarterly margins can vary based on seasonality, geographic and product mix, production volumes, and potential price compression. She said the company believes trailing 12-month gross-margin performance provides more useful context than any one quarter.

Operating expenses totaled $21 million, up $1.2 million year over year. The increase reflected higher sales and marketing, research and development, and general and administrative spending. About $500,000 of the increase was related to transaction costs, primarily tied to Cronos’ pending acquisition of CanAdelaar in the Netherlands.

Israel posts 10th consecutive quarter of record revenue Cronos Israel delivered its 10th consecutive quarter of record net revenue, with sales rising 60% year over year, or 32% on a constant-currency basis, according to Gorenstein. He said the company’s PEACE NATURALS brand continued to extend its lead in Israel’s medical cannabis market based on pharmacy data collected by Cronos.

Lord Jones, meanwhile, completed its second quarter of sales in Israel and was gaining momentum in the premium flower segment, Gorenstein said.

The company also addressed a newly announced investigation by the Trade Levies Commissioner of Israel’s Ministry of Economy and Industry into alleged dumping of medical cannabis imports from Canada. Gorenstein said Cronos disputes the allegations and will cooperate with the ministry. He noted that a previous investigation into similar claims did not result in an anti-dumping duty.

“Cronos does not engage in dumping,” Gorenstein said, adding that the company previously submitted pricing and cost data showing its Israeli pricing was not below its Canadian pricing.

Despite geopolitical and regulatory challenges in Israel, Gorenstein said Cronos remains committed to the market. The company has invested more than ILS 100 million in a greenhouse, manufacturing facility and cannabinoid research-and-development laboratory, and employs approximately 80 people in the country.

Spinach gains share across Canadian categories In Canada, Cronos recorded its highest quarterly net revenue, while its brands generated 25% year-over-year retail sales growth compared with 1% industry-wide sales growth, according to Hifyre data cited by the company.

The Spinach brand retained its No. 1 position in vapes for the second consecutive quarter, expanding total vape market share to 10.6%. In vape cartridges, Spinach remained No. 1 for the third consecutive quarter, with 11.8% share. The brand ranked second in disposable vapes, where its share increased to 8.2%, aided by the PUFFERZ all-in-one offering launched late in 2025.

Cronos launched three PUFFERZ flavors during the quarter: Strawberry Burst, Peach Iced Tea and Grape Gas. It also introduced the Spinach Orange Vanilla Twist one-gram cartridge as the brand’s first limited-time summer vape cartridge offering.

Spinach remained Canada’s top edible brand for the eighth consecutive quarter, with 20.8% market share and 22.5% share within gummies. Five SOURZ by Spinach Fully Blasted products ranked among Canada’s top 10 edible stock-keeping units, including the Fully Blasted Blue Raspberry Watermelon 10-pack, which ranked first nationally.

In flower, Spinach ranked third with a 5.4% market share. GMO Cookies and OG Kush were among the country’s six top-selling flower products during the quarter. Spinach also rose to seventh place in pre-rolls, with a 3.1% share, while gaining ground in infused and traditional pre-rolls.

Germany growth and Netherlands acquisition remain in focus Outside Israel, Cronos’ international net revenue increased 88% year over year, led by demand in Germany. Gorenstein said the company’s additional supply capacity has allowed it to place greater focus on Europe, while its approach remains centered on delivering a competitive product offering rather than avoiding competitive markets.

Gorenstein also said GrowCo is fully online and that Cronos expects further operational efficiencies as it continues refining the facility, manufacturing processes and genetic breeding program. He said the added flower supply has supported gains across flower, pre-rolls and vapes while helping the company maintain its edible-market leadership.

Regarding CanAdelaar, Gorenstein said the Netherlands business was performing in line with Cronos’ expectations. The company expects to close the acquisition in the second half of 2026, subject to Dutch regulatory clearance and remaining closing conditions. Cronos has not been informed of specific issues with its regulatory submission, he said.

CanAdelaar is the largest company participating in the Netherlands’ legal adult-use cannabis program, according to Cronos. Gorenstein said the acquisition could create an opportunity to introduce adult-use products such as SOURZ by Spinach and PUFFERZ into the Dutch market.

Cronos ended the quarter with $827 million in cash equivalents, short-term investments and non-current interest-bearing deposits, up $5 million from the first quarter. The increase reflected $24 million in positive operating cash flow, partly offset by $60 million in share repurchases and $2 million in capital expenditures.

The company also held a $17 million loan receivable, a $15 million current income tax receivable and $5 million in other investments. Gorenstein said Cronos remains active under its share repurchase program and views buybacks as an attractive use of capital while maintaining flexibility to invest in growth opportunities.

About Cronos Group (NASDAQ:CRON)Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group's business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company's branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Cronos Group Right Now?Before you consider Cronos Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cronos Group wasn't on the list.

While Cronos Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q2 2026 increased by 51% year-over-year on an organic, constant-currency basis Delivered record net revenue in Canada, with Spinach® maintaining #1 market share in vapes and edibles1 Tenth consecutive quarter of record net revenue in Israel, where PEACE NATURALS® continues to be the #1 cannabis brand2 Generated record net revenue outside Canada and Israel, led by strong demand for PEACE NATURALS® in Germany Repurchased 12.3 million shares in the first half of 2026 TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2026 second quarter business results. “Cronos delivered a record second quarter by organically achieving record net revenue, record gross profit and record Adjusted EBITDA, while also reducing our share count.

PARIS--(BUSINESS WIRE)--TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) (50%) and Eni (50%, operator), partners in Cyprus offshore Block 6, have taken the Final Investment Decision (FID) for the development of the Cronos gas field, discovered in 2022 and successfully appraised in 2024. Located in deep offshore waters approximately 185 kilometers southwest of the coast of Cyprus, Cronos will be developed through four subsea wells. The gas will be transported by subsea pipeline from Cypriot waters.

July 16, 2026 07:30 ET  | Source: Cronos Group Inc.

TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.

To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company’s website.

About Cronos

Cronos is a global cannabis company focused on scaling leading consumer goods products through R&D and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT™ and Lord Jones®. For more information about Cronos and its brands, please visit: https://thecronosgroup.com/.

Forward-looking Statements

This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about Cronos’ intention to build an iconic brand portfolio and its focus on scaling leading consumer goods products through R&D and innovation. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, each of which have been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

Cronos Contact
Harrison Aaron
Investor Relations
Tel: (416) 504-0004
[email protected]

This Is How Marijuana Stock Investors Can See Bigger Gains

2 minute read Here Are 3 Of The Best Marijuana Stock Investment Options In 2026 As the cannabis sector continues to grow, it has marijuana stock investors seeing green. There has been a long, volatile battle for most of the time cannabis companies have been publicly traded. Even during the moments when many used pot stocks to get quick profits, given how the sector once began. At one point, a great deal of hype and speculation fueled investors in taking up positions for particular cannabis stocks.

For those who are still in it and see a greener future with marijuana stocks, this year seems to be another turning point. Now, if you have been active in cannabis investing for the last decade, 2026 can end with some decent profits. However, this is not set in stone, but the way things are developing from a legal and operational standpoint could help shareholders become more profitable. Right now in the USA, cannabis has been reclassified, and in Canada it is outright legal, as well as in Europe.

All of which are global points that fuel some of the biggest legal cannabis markets in the world. Even in a volatile space led with long downtrend signs, successful operations show there is potential down the road for the same to occur in the public sector. Below are some top marijuana stocks to watch in 2026 that help make you more money.

Top Canadian Marijuana Stocks For Your Portfolio Tilray Brands, Inc. (NASDAQ:TLRY) Canopy Growth Corporation (NASDAQ:CGC) Cronos Group Inc. (NASDAQ:CRON) Tilray Brands, Inc. Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally.

In more recent news, the company announced it has strengthened its global medical cannabis platform and Canadian patient access through the HelloMD acquisition. The acquisition will strengthen Tilray’s global medical cannabis platform by expanding direct-to-patient capabilities.

[Read More] Looking for Cannabis Growth? Watch These 3 Marijuana Stocks in July 2026

Canopy Growth Corporation Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally.

Back on June 8th, the company announced that Claybourne’s Frosted Flyers won best infused pre-roll at the 2026 Growup Awards.

[Read More] Looking for Cannabis Growth? Watch These 3 Marijuana Stocks in July 2026

Cronos Group Inc. Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally.

The company recently announced the appointment of ATM Cormakr as its broker for share repurchases in Canada.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]

Key Takeaways CRON reported Q1 net revenues up 40% to $45.2M and gross profit up 39% to $19.2M.CRON's brands grew retail sales 18% in Canada; Spinach became the top vape brand.CRON expanded in Israel and Germany, while CanAdelaar closing shifted to summer 2026. Cronos Group (CRON - Free Report) continues to attract investor attention as the cannabis company strengthens its global footprint and executes on several strategic initiatives.

The company has been expanding its presence across international markets while reinforcing its position in Canada through a growing portfolio of cannabis brands. At the same time, Cronos' strong balance sheet provides the financial flexibility to pursue additional growth opportunities.

These developments raise an important question for investors: Do they make the cannabis stock an attractive investment opportunity at current levels? Let’s examine the company’s fundamentals to better assess the appropriate course of action.

CRON’s Encouraging Q1 ResultsCronos Group delivered encouraging first-quarter 2026 results, reflecting strength across both its domestic and international operations.

Net revenues increased 40% year over year to $45.2 million, driven by higher cannabis flower sales in Israel, Canada and other international markets, as well as higher cannabis extract sales in Canada. Gross profit increased 39% year over year to $19.2 million, benefiting from higher sales volumes and a favorable product mix.

The quarter also highlighted the strength of Cronos' Canadian business. Its brands generated 18% year-over-year retail sales growth, significantly outpacing the industry's 2% growth rate. Spinach became the No. 1 vape brand in Canada during the quarter, while the company maintained its leadership position in edibles and improved its standing in the flower category as production constraints eased following the expansion of its GrowCo cultivation operations.

Cronos also continued to expand its international footprint, with Israel and Germany remaining important growth markets. Meanwhile, the completion timeline for the CanAdelaar acquisition has been pushed out, with management now expecting the transaction to close in the summer of 2026, subject to certain closing conditions.

Cutthroat CompetitionDespite recent positive developments, Cronos continues to operate in an intensely competitive cannabis market. The company faces pressure from peers, such as Aurora Cannabis (ACB - Free Report) and Tilray Brands (TLRY - Free Report) .

Both ACB and TLRY are actively pursuing international expansion opportunities and product portfolio diversification. Sustaining market share gains and pricing power could remain challenging as more players target the same growth markets.

CRON Stock Performance & EstimateYear to date, shares of the Canada-based cannabis operator have risen more than 2% against the industry’s nearly 7% fall.

Image Source: Zacks Investment Research

Bottom-line estimates for 2026 have remained unchanged over the past 30 days, indicating stable earnings expectations in the near term.

Image Source: Zacks Investment Research

How to Play CRON Stock?Cronos is making steady progress across multiple areas of its business, supported by strong first-quarter results, improving brand performance in Canada and continued international expansion efforts.

However, the company continues to operate in a highly competitive industry, while some of its longer-term growth initiatives remain subject to execution and regulatory risks. While Cronos continues to execute on its strategic initiatives, analysts remain cautious about the pace at which these efforts will translate into sustained earnings growth.

Given these factors, investors may prefer to remain cautious on the stock at the current levels. CRON currently carries a Zacks Rank #4 (Sell), indicating that investors may be better off staying on the sidelines for now.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

June 22, 2026 17:30 ET  | Source: Cronos Group Inc.

TORONTO, June 22, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) today announced that at its Annual Meeting of Shareholders held on Thursday, June 18, 2026 (the “Meeting”), shareholders holding a total of 271,828,759 common shares of the Company voted in person or by proxy, representing 72.24% of the total number of common shares of the Company outstanding.

Each of the directors listed as a nominee in the Company’s definitive proxy statement dated April 24, 2026, was elected as a director of the Company, with each director receiving in excess of 93.6% of the votes cast in favor of his or her election. The detailed results of the vote for the election of directors are as follows:

Name of DirectorNumber of Shares Voted ForPercentage of Shares Voted ForNumber of Shares Withheld from VotingPercentage of Shares Withheld from VotingJason Adler220,505,353  99.42 %1,291,292  0.58 %Darren Broughton220,506,387  99.42 %1,290,258  0.58 %Murray Garnick219,627,749  99.02 %2,168,896  0.98 %Michael Gorenstein207,751,369  93.67 %14,045,276  6.33 %Dominik Meier220,426,444  99.38 %1,370,201  0.62 %James Rudyk216,463,958  97.60 %5,332,687  2.40 %Elizabeth Seegar220,476,757  99.40 %1,319,888  0.60 %
Shareholders also approved an advisory (non-binding) resolution on the compensation of the Company’s named executive officers, with 99.09% of votes cast in favor of such resolution, and voted, on an advisory (non-binding) basis, in favor of holding future advisory votes on the compensation of the Company’s named executive officers every year. Shareholders also approved the appointment of Davidson & Company LLP as the Company’s independent auditor for fiscal year 2026 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration.

For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company’s SEDAR+ profile at www.sedarplus.com and the Company’s Form 8-K filed on EDGAR at www.sec.gov/edgar.

About Cronos

Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT™ and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

For further information, please contact:
Harrison Aaron
Investor Relations
Tel: (416) 504-0004
[email protected]

Shares of Cronos Group CRON have staged a strong recovery over the past year. The Canada-based cannabis operator's shares have risen 46% in the said time frame, significantly outperforming the industry, as shown in the chart below.

Top 3 Canadian Cannabis Stocks to Watch in April 2026 The Canadian cannabis sector continues to evolve in 2026, even as volatility remains elevated. Total Canadian cannabis sales have steadily increased in recent years, showing consistent demand growth. However, pricing pressure and competition continue to challenge margins across the industry. Still, leading companies are adapting through international expansion, scale in retail, and diversification. As a result, investors are closely watching key names for potential upside during sector recoveries.

In addition, U.S. reform headlines and global medical demand remain long-term catalysts. Many Canadian operators are positioning themselves for cross-border opportunities. Therefore, understanding a company’s fundamentals is critical before taking a position. Technical analysis and proper risk management remain essential in this volatile sector. With that in mind, here are three top Canadian cannabis stocks to watch in April 2026.

[Read More] 3 Top Marijuana Stocks For Better Trading And Investing

Canadian Cannabis Stocks to Watch in April 2026 for Growth Investors Aurora Cannabis Inc. (NASDAQ: ACB) Cronos Group Inc. (NASDAQ: CRON) SNDL Inc. (NASDAQ: SNDL) Aurora Cannabis Inc. (ACB) Aurora Cannabis Inc. remains one of the most recognized Canadian cannabis producers. The company has shifted focus toward high-margin medical cannabis markets. Its largest presence is in international markets such as Germany and Australia. However, Aurora has a limited direct U.S. retail footprint compared to MSOs. Instead, it leverages global distribution partnerships and medical channels.

The company operates production facilities across Canada and key international markets. Aurora does not operate a large U.S. dispensary network. However, it maintains a strategic position for future U.S. expansion. This approach allows flexibility if federal legalization occurs. Additionally, Aurora has streamlined operations to focus on premium medical cannabis. As a result, management continues prioritizing profitability over aggressive expansion.

Financially, Aurora has shown mixed but improving results in recent quarters. The company has reported quarterly revenue in the mid-tens of millions range. However, it has occasionally missed analyst expectations during recent earnings reports. Despite this, medical cannabis revenue continues to grow steadily. Aurora has also shown improvements in free cash flow and operating margins.

Furthermore, the company maintains a relatively strong balance sheet with improved cost discipline. It has also reported better adjusted EBITDA compared to prior periods. Still, net losses remain a concern for investors in the near term. Overall, Aurora is transitioning into a more sustainable business model. Therefore, it remains a speculative but potentially rewarding play.

[Read More] Best U.S. Cannabis Stocks for April 2026: Growth, Scale, and Opportunity

Cronos Group Inc. (CRON) Cronos Group Inc. stands out due to its strong strategic partnerships and global ambitions. The company has backing from a major tobacco partner, which provides financial support. This partnership also supports product innovation and long-term development strategies. As a result, Cronos has focused heavily on brand building and cannabinoid research.

Unlike U.S. multi-state operators, Cronos does not operate a large dispensary network. Instead, it focuses on branded products and international distribution channels. The company has a growing presence in markets like Israel and Canada. Additionally, Cronos continues developing cannabinoid-based products beyond traditional flower offerings.

In the U.S., Cronos has positioned itself for future entry through strategic investments. However, it currently does not operate any domestic dispensaries. This asset-light approach reduces operational risk but limits near-term revenue growth. Still, the company benefits from a strong balance sheet and minimal debt exposure.

Financially, Cronos has maintained a relatively stable position compared to many competitors. The company continues generating revenue from cannabis and derivative product sales. However, profitability remains a challenge across the broader cannabis sector. Cronos has focused on cost controls and margin improvement initiatives.

Moreover, the company maintains a large cash position, providing long-term flexibility. This allows Cronos to navigate market downturns more effectively than its peers. While revenue growth has been slower, management emphasizes quality and sustainability. Therefore, Cronos remains a long-term strategic play in the cannabis sector.

[Read More] Best Cannabis REITs and Lenders to Watch This April 2026

SNDL Inc. (SNDL) The company has undergone a major transformation over the past few years. SNDL Inc. has evolved into a diversified cannabis and retail operator. Its largest presence is in Canada through an extensive retail store network. SNDL operates a large number of cannabis retail locations across the country.

Additionally, SNDL owns several well-known retail banners, including Value Buds and Spiritleaf. This provides strong exposure to consumer demand trends at the retail level. Unlike many competitors, SNDL has built a vertically integrated business model. It combines cultivation, production, and retail operations under one structure.

In the U.S., SNDL has limited direct exposure but holds strategic investment positions. These investments offer optional upside for future expansion. Furthermore, the company has diversified into liquor retail operations. This adds another stable revenue stream and reduces reliance on cannabis alone.

Financially, SNDL has shown notable improvement in recent years. The company has generated strong annual revenue compared to previous periods. Additionally, losses have narrowed significantly, indicating better cost management. This reflects improved operational efficiency across its business segments.

SNDL has also reported strong growth in its cannabis and retail divisions. Retail operations have contributed heavily to total revenue performance. Furthermore, the company continues deploying capital into strategic investments. Overall, SNDL stands out for its scale and diversification. Therefore, it remains one of the more stable Canadian cannabis stocks to watch.

[Read More] Here Are Ways Marijuana Stocks Make Better Long-Term Investments

Final Thoughts The Canadian cannabis sector remains in a transitional phase in 2026. Growth continues, but challenges like pricing pressure and competition persist. However, leading companies are adapting through strategic changes and diversification efforts.

Aurora Cannabis offers exposure to global medical markets and opportunities to improve efficiency. Cronos Group provides a strong balance sheet and long-term innovation potential. Meanwhile, SNDL delivers scale through its retail dominance and diversified operations.

As always, investors should combine fundamental analysis with technical setups. Risk management remains critical in such a volatile sector. However, for those seeking exposure, these three stocks offer compelling opportunities to watch in April 2026.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]

Here Is How Speculation Can Cauase Marijuana Stocks To Run

3 minute read What Goes In Cannabis Industry Impacts Marijuana Stocks Means To Trade Up Marijuana stock investors are still in a position where volatility and speculation control the outcome. Especially with all the laws and regulatory changes that have transformed the cannabis industry. All of which has an impact on how the public sector behaves. When an investor speculates, whether for better or worse, it can lead to others following suit, and this typically creates more momentum for the sector as a whole. As the current state of the cannabis sector has not changed much in this regard, investors are keeping a close eye on any upward shifts in trading.

By having a plan and staying prepared, this is a recipe that will help shareholders take profits when the time comes. So far in 2026, more people have shown an increased interest in legal cannabis. The sector is becoming seen as more legitimate, and this calms the minds of investors. At one point, there was a lot of fear due to cannabis and federal restrictions.

However, today that is not the case, and things are evolving and growing even further. In Q2 2026, the cannabis industry is looking to further its growth and meet the demands for both recreational and medical markets. Hopefully, the success that is occurring helps the public sector sooner rather than later. Below are some top marijuana stocks to watch for better trading.

Top Marijuana Stocks For Investors Tilray Brands, Inc. (NASDAQ:TLRY) Canopy Growth Corporation (NASDAQ:CGC) Cronos Group Inc. (NASDAQ:CRON) Tilray Brands, Inc. Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. 

In recent news, the company has accelerated the next phase of global growth and market leadership.

Words From The Company Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, stated: “Tilray Brands is setting the pace for global innovation across healthcare, cannabis, and craft beverages – each a distinct growth engine within our platform. This is a defining moment as we enter our next phase of global growth.

Canopy Growth Corporation Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia.

In more recent updates, the company has acquired a 36-unit townhome community in Mesa for $13.39 million.

[Read More] 3 Top Marijuana Stocks For Long-Term Investing 2026

Cronos Group Inc. Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally.

Over the last month or so, the company has reported 2 updates, one of which is that they have recently presented at the 38th Annual ROTH Conference back on March 23, 2026. As well, Cronos Group Inc. also reported its Q4 2025 financial results.

[Read More] Cannabis REITs Positioned for Growth in 2026

Q4 2025 Highlights Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million Achieved record net revenue in Q4 2025 and FY 2025 Eighth consecutive quarter of record net revenue in Israel, where PEACE NATURALS® continues to be the number one cannabis brand Industry-leading balance sheet with $832 million in cash and cash equivalents and short-term investments MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]

Posted by Defense World Staff on Apr 25th, 2026

Cronos Group (NASDAQ:CRON – Get Free Report) and Incannex Healthcare (NASDAQ:IXHL – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Recommendations This is a summary of current recommendations and price targets for Cronos Group and Incannex Healthcare, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 1 2 2 0 2.20 Incannex Healthcare 1 0 0 0 1.00 Cronos Group currently has a consensus price target of $2.30, indicating a potential downside of 14.18%. Given Cronos Group’s stronger consensus rating and higher probable upside, equities analysts plainly believe Cronos Group is more favorable than Incannex Healthcare.

Profitability This table compares Cronos Group and Incannex Healthcare’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Cronos Group -6.44% -1.12% -1.07% Incannex Healthcare N/A -114.95% -103.38% Earnings & Valuation This table compares Cronos Group and Incannex Healthcare”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group $146.59 million 6.88 -$9.45 million ($0.01) -268.00 Incannex Healthcare N/A N/A -$46.88 million ($8.41) -0.48 Cronos Group has higher revenue and earnings than Incannex Healthcare. Cronos Group is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership 8.7% of Cronos Group shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 7.3% of Cronos Group shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility Cronos Group has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 7.5, suggesting that its stock price is 650% more volatile than the S&P 500.

Summary Cronos Group beats Incannex Healthcare on 10 of the 13 factors compared between the two stocks.

About Cronos Group (Get Free Report)

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

About Incannex Healthcare (Get Free Report)

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECRH (NYSE:CRH) vs. Grafton Group (OTCMKTS:GROUF) Head to Head Comparison

NEXT HEADLINE »Head-To-Head Contrast: Zurich Insurance Group (OTCMKTS:ZURVY) & Hippo (NYSE:HIPO)

April 29, 2026 07:30 ET  | Source: Cronos Group Inc.

TORONTO, April 29, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 Annual Meeting of Shareholders on Thursday, June 18, 2026, at 11:00 a.m. ET.

Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2026 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote.

The Company’s proxy statement describing the formal business to be conducted at the meeting and containing detailed instructions about how to participate in the meeting is available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/financial-information/annual-meeting.

Access Information
Date: Thursday, June 18, 2026
Time: 11:00 a.m. ET
Live Audio Webcast Online at: http://www.virtualshareholdermeeting.com/CRON2026

Replay
A replay of the Annual Meeting will be available in the investor relations section of the Company’s website (https://ir.thecronosgroup.com/events-presentations) starting about 24 hours after the meeting is finished.

About Cronos
Cronos is an innovative global cannabis company focused on scaling leading consumer goods products through R&D and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT®, and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

Forward-looking Statements
This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about the Company's innovation strategy and development of high-quality consumer goods products; and Cronos’ intention to build an international iconic brand portfolio and develop disruptive intellectual property by advancing cannabis research, technology and product development. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which has been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

Cronos Group Contact
Harrison Aaron
Investor Relations
Tel: (416) 504-0004
[email protected]

Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million

Achieved record net revenue and gross profit in Q1 2026

Reached #1 market share in vapes in Canada1

Ninth consecutive quarter of record net revenue in Israel, where PEACE NATURALS® continues to be the number one cannabis brand2

Industry-leading balance sheet with $822 million in total cash and cash equivalents

TORONTO, May 11, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2026 first quarter business results.

“Cronos delivered record net revenue and gross profit in the first quarter, as we continue to execute against our borderless products strategy and as additional supply from the expansion at Cronos GrowCo fuels our next phase of growth. Cronos Israel delivered another record quarter, further cementing PEACE NATURALS® as the #1 cannabis brand in the country. In other international markets, we achieved record quarterly net revenue, and we continue to see robust growth potential for our products in Europe. In Canada, the Spinach® brand claimed the #1 position in vapes for the first time, while maintaining its outstanding #1 ranking in edibles,1 a testament to the strength of our brand portfolio and our innovation platform,” said Mike Gorenstein, Chairman, President and CEO of Cronos.

“We are executing on a clear and focused growth strategy. We are benefitting from increased volume following Cronos GrowCo’s expansion and sustained growth in our proprietary products across categories, with significant momentum in international markets, positioning Cronos to deliver sustainable net revenue and Adjusted EBITDA growth. Our pending acquisition of CanAdelaar, the leading operator in the Netherlands’ legal market, is expected to establish a strategic footprint for Cronos in Europe and enable us to leverage our borderless product strategy in a scaled adult-use market. Backed by an industry-leading balance sheet, we have the financial strength and flexibility to invest with discipline and deliver value to our shareholders.”

Consolidated Financial Results

The tables below set forth our condensed consolidated results of operations, expressed in thousands of United States (“U.S.”) dollars for the periods presented. Our condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that we will achieve in future periods.

(in thousands of USD)Three months ended March 31, Change  2026   2025  $ %Net revenue$45,210  $32,262  $12,948  40%        Cost of sales 25,392   18,528   6,864  37%Inventory write-down 665   —   665  N/AGross profit$19,153  $13,734  $5,419  39%Gross margin(i) 42%  43% N/A (1)pp        Inventory step-up recorded to cost of sales —   517   (517) N/AAdjusted Gross Profit(ii)$19,153  $14,251  $4,902  34%Adjusted Gross Margin(iii) 42%  44% N/A (2)pp        Net income$15,711  $7,723  $7,988  103%        Adjusted EBITDA(ii)$5,079  $2,289  $2,790  122%        Other Data       Cash and cash equivalents(iv)$821,856  $797,819  $24,037  3%Short-term investments(iv) —   40,000   (40,000) N/ACapital expenditures(v) 1,971   15,356   (13,385) (87)% (i)   Gross margin is defined as gross profit divided by net revenue.
(ii)   See “Non-GAAP Measures” for more information, including a reconciliation of adjusted earnings (loss) before interest, taxes, depreciation and amortization (“Adjusted EBITDA”) to net income (loss) and a reconciliation of Adjusted Gross Profit to gross profit.
(iii)   Adjusted Gross Margin is defined as Adjusted Gross Profit divided by net revenue. See Non-GAAP Measures for more information.
(iv)   Dollar amounts are as of the last day of the period indicated.
(v)   Capital expenditures represent component information of investing activities and is defined as the sum of purchase of property, plant and equipment, and purchase of intangible assets.

First Quarter 2026

Net revenue of $45.2 million in Q1 2026 increased by $12.9 million from Q1 2025. The increase was primarily due to higher cannabis flower sales in Israel and other countries, which carry no excise taxes, and higher cannabis extract and flower sales in the Canadian market.Gross profit of $19.2 million in Q1 2026 increased by $5.4 million from Q1 2025. The increase was primarily due to higher average sales prices, largely driven by a mix shift to Israel and other countries, which carry no excise taxes, and higher sales volumes. For the three months ended March 31, 2025, gross profit was reduced by $0.5 million as a result of the impact of the inventory step-up from the transaction (the “Cronos GrowCo Transaction”) by which we obtained majority control of the board of directors of Cronos Growing Company Inc. (“Cronos GrowCo”) that was recorded into cost of sales. No such costs were recognized for the three months ended March 31, 2026.Adjusted Gross Profit of $19.2 million in Q1 2026 increased by $4.9 million from Q1 2025. The increase was primarily due to higher average sales prices, largely driven by a mix shift to Israel and other countries, which carry no excise taxes, and higher sales volumes.Net income of $15.7 million in Q1 2026 increased by $8.0 million from Q1 2025. The increase was primarily due to higher gross profit and other income, partially offset by higher operating expenses.Adjusted EBITDA of $5.1 million in Q1 2026 improved by $2.8 million from Q1 2025. The improvement was primarily driven by higher gross profit, partially offset by higher operating expenses due to higher sales and marketing, general and administrative, and research and development (“R&D”) costs.
Business Updates

Renewed Share Repurchase Authorization

On May 8, 2026, the Board unanimously authorized a share repurchase program of up to $50 million, which is intended to succeed the Company’s existing share repurchase program upon its scheduled expiration on May 13, 2026. The share repurchase program is expected to commence on May 14, 2026 and terminate on May 13, 2027, unless earlier terminated. Repurchases under the program may be made from time to time, either through open market purchases at then-prevailing market prices through the facilities of the Nasdaq Global Market or other U.S. published markets, privately negotiated transactions or otherwise. Open market repurchases will be limited to 5% of the number of common shares outstanding as of the applicable measurement time, the maximum amount permitted by applicable securities laws. The timing and amount of repurchases are subject to market conditions, compliance with applicable laws and regulations and any other factors management of the Company may deem relevant. The program does not obligate Cronos to acquire any specific dollar amount or number of shares and may be modified, suspended, or discontinued at any time.

From May 14, 2025 through May 6, 2026, Cronos repurchased a total of 13,394,475 shares at a cost of approximately $33.5 million, inclusive of commissions and excise taxes.

Brand and Product Portfolio

Spinach®3

The Spinach® brand delivered outstanding results in Q1 2026, reinforcing its standing among Canada’s favorite cannabis brands. The brand held 5.5% total market share nationally, maintaining its position as the #2 brand in Canada. In flower, the Spinach® brand rose to #3 with 5.0% market share, reflecting increased product availability following the Cronos GrowCo expansion and continued consumer demand for the brand’s core offerings.

The Spinach® brand’s most significant achievement in Q1 2026 was reaching #1 in the vape category for the first time in the brand’s history, capturing 9.8% total vape market share across all formats in Canada, a milestone that underscores the brand’s growing strength in one of Canada’s fastest-growing cannabis categories. In vape cartridges specifically, Spinach® reached 11.1% market share in the quarter, also ranking #1, and the three best-selling vape SKUs nationwide across all formats were Spinach® vape cartridges. Canadian distribution of Spinach® PUFFERZTM all-in-one vapes broadened in the quarter, with PUFFERZTM reaching the #2 market share position in all-in-one vapes in March 2026, just four months after launch.

In edibles, Spinach® retained its outstanding #1 position with a 20.8% share of the Canadian market, powered by the continued success of SOURZ by Spinach® gummies, which held 22.7% of the gummies segment. In Q1 2026, four SOURZ by Spinach® gummies products ranked among the top 10 edibles nationally, including the top-selling edibles SKU in Canada, the Fully Blasted Blue Raspberry Watermelon 10 Pack.

During Q1 2026, Cronos launched a series of new pre-roll products for the Canadian market, including limited edition Sour Chem and Space Cake 10 x 0.4g Spinach® STIX and Sour Chem and GMO Cookies 2 x 1g Spinach® pre-rolls, offering consumers distinctive and accessible ways to experience the brand’s most popular genetics.

PEACE NATURALS®4

Cronos Israel delivered another record quarter in Q1 2026, with the PEACE NATURALS® brand expanding its lead in the Israeli medical cannabis market, resulting in net revenue growth of 53% year-over-year. The sustained leadership of PEACE NATURALS® products reflects the strength of Cronos’ advanced genetic breeding program, and industry-leading cultivation capabilities.

Cronos continued to build on its international presence in Q1 2026, with net revenue in international markets outside Israel growing 97% year-over-year, reaching record levels in the quarter. The Company’s global platform continues to be a key differentiator, enabling Cronos to leverage its genetics, cultivation expertise, and brand equity across multiple regulatory environments and patient populations.

LIT™

In Q1 2026, Cronos further expanded sales of its value-focused medical brand LIT™ across Israel and Europe, reflecting the Company’s strategy of building a tiered product portfolio, from premium to accessible price points, that serves the spectrum of medical cannabis patients.

Lord Jones®5

The Lord Jones® brand continued to serve the premium cannabis consumer in Q1 2026, with a focused presence across several key categories. The brand held a 9.1% market share in chocolate cannabis edibles, ranking #3 in Canada.

The Lord Jones® brand also made its entry into the Israeli medical cannabis market in Q1 2026, where its five premium flower strains were met with strong demand from patients. The brand’s expansion into Israel underscores Cronos’ commitment to thoughtful international growth driven by disciplined execution and differentiated brand experiences.

CanAdelaar Acquisition

On December 9, 2025, the Company entered into a definitive share sale and purchase agreement (the “SPA”) to acquire all of the issued and outstanding shares of CanAdelaar B.V. (“CanAdelaar”), one of ten licensed cannabis producers participating in the Dutch Controlled Cannabis Supply Chain Experiment.

On May 8, 2026, the Company entered into an amendment to the SPA pursuant to which the parties agreed to extend the Long Stop Date (as defined in the SPA) for closing of the acquisition from June 9, 2026 to September 9, 2026. The extension provides additional time to satisfy certain closing conditions, including obtaining required regulatory clearances in the Netherlands, receipt of confirmations relating to CanAdelaar’s licenses and completion of the Bibob review (a background check conducted by Dutch authorities). No other material changes were made to the terms of the transaction.

The Company expects the acquisition to close in the summer of 2026.

Conference Call

The Company will host a conference call and live audio webcast on Monday, May 11, 2026, at 8:30 a.m. ET to discuss 2026 first quarter business results. An audio replay of the call will be archived on the Company’s website for replay. Instructions for the live audio webcast are provided on the Company’s website at https://ir.thecronosgroup.com/events-presentations.

About Cronos

Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT™ and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

Forward-Looking Statements

This press release contains information that may constitute forward-looking information and forward-looking statements within the meaning of applicable U.S. and Canadian securities laws and court decisions (collectively, “Forward-Looking Statements”), which are based upon our current internal expectations, estimates, projections, assumptions and beliefs. Information that is not clearly historical in nature may constitute Forward-Looking Statements. In some cases, Forward-Looking Statements can be identified by the use of forward-looking terminology, such as “expect,” “likely,” “may,” “will,” “should,” “intend,” “anticipate,” “potential,” “proposed,” “estimate,” “believe,” “plan” and other similar words, expressions and phrases, including negative and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussion of strategy. Forward-Looking Statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of historical fact.

Forward-Looking Statements include, but are not limited to, statements with respect to:

the ongoing impact of the public investigation into Canadian licensed producers of alleged dumping of medical cannabis imports from Canada into Israel by the Trade Levies Commissioner of the Israel Ministry of Economy and Industry (the “Anti-Dumping Investigation”) and the proposed anti-dumping duty to which the Company’s imports would be subject;expectations related to the conflict involving the United States, Israel, Hamas, Hezbollah, Houthis, Iran, Iran’s proxies and other stakeholders in the region (the “Middle East Conflict”) and its impact on our operations in Israel, the supply of product in the market and the demand for product by medical patients in Israel, as well as any regional or global escalations and their impact to global commerce and stability;expectations related to markets outside of Canada and Israel, and our ability to successfully distribute the PEACE NATURALS® brand in those markets;expectations related to the impact of our decision to exit our U.S. hemp-derived cannabinoid product operations and any future plans to re-enter the U.S. market;the ongoing impact of our announced realignment (inclusive of any revisions thereto, the “Realignment”) and any progress, challenges and effects related thereto as well as changes in strategy, metrics, investments, reporting structure, costs, operating expenses, employee turnover and other changes with respect thereto;our expectations as to the use and expansion of our facility in Stayner, Ontario (the “Peace Naturals Campus”);our ability to acquire raw materials from suppliers, including Cronos GrowCo, and the costs and timing associated therewith;expectations regarding the potential success of, and the costs and benefits associated with, our joint ventures, strategic alliances and equity investments;expectations related to the expansion of Cronos GrowCo’s purpose-built cultivation and processing facilities and any additional supply or growth opportunities (including in the wholesale market) provided thereby;expectations related to the transaction by which we, as lender, obtained junior secured convertible debt (the “High Tide Loan”) from High Tide Inc. (“High Tide”), as borrower, and a warrant (the “High Tide Warrant”) to purchase common shares of High Tide, the performance of the High Tide Loan and the High Tide Warrant, and High Tide’s ability to repay the High Tide Loan;expectations related to our agreement to acquire CanAdelaar, including the timing and completion of the transaction, and the anticipated costs, benefits and integration matters associated therewith and the performance of the business from and following closing;expectations related to the impact of the renewed share repurchase program that was authorized on May 8, 2026, including the timing and amount of repurchases;our ability or plans to identify, develop, commercialize or expand our technology and R&D initiatives in cannabinoids, or the success thereof;expectations regarding revenues, expenses, gross margins and capital expenditures;expectations regarding our future production and manufacturing strategy and operations, the costs and timing associated therewith and the receipt of applicable production and sale licenses;the ongoing impact of the legalization of additional cannabis product types and forms for adult-use in Canada, including federal, provincial, territorial and municipal regulations pertaining thereto, the related timing and impact thereof and our intentions to participate in such markets;the legalization of the use of cannabis for medical or adult-use in jurisdictions outside of Canada, the related timing and impact thereof and our intentions to participate in such markets, if, when and to the extent such use is legalized;the grant, renewal, withdrawal, suspension, delay and impact of any license or supplemental license to conduct activities with cannabis or any amendments thereof;our ability to successfully create, launch and scale brands and cannabis products;expectations related to the differentiation of our products, including through the utilization of rare cannabinoids;the benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, including CBD and other cannabinoids;laws and regulations and any amendments thereto applicable to our business and the impact thereof, including uncertainty regarding the application of U.S. state and federal law to cannabis and U.S. hemp (including CBD and other U.S. hemp-derived cannabinoids) products and the scope of any regulations by the U.S. Department of Health and Human Services, U.S. Food and Drug Administration, the U.S. Drug Enforcement Administration, the U.S. Federal Trade Commission, the U.S. Patent and Trademark Office and any state equivalent regulatory agencies over cannabis and U.S. hemp (including CBD and other U.S. hemp-derived cannabinoids) products, including the final order issued by the U.S. Department of Justice (the “DOJ”) moving certain categories of marijuana products from Schedule I to Schedule III under the U.S. Controlled Substances Act and any future actions that may be taken or considered by the DOJ or other government agencies;the anticipated benefits and impact of Altria Group, Inc.’s investment in the Company (the “Altria Investment”), pursuant to a subscription agreement dated December 7, 2018;expectations regarding the implementation and effectiveness of key personnel changes;expectations regarding business combinations and dispositions and the anticipated benefits therefrom;expectations of the amount or frequency of impairment losses, including as a result of the write-down of intangible assets, including goodwill;the impact of the ongoing military conflict between Russia and Ukraine (and resulting sanctions) on our business, financial condition and results of operations or cash flows;our compliance with the terms of the settlement (the “Settlement Order”) with the SEC and the settlement agreement with the Ontario Securities Commission (the “OSC”); andthe impact of the loss of our ability to rely on private offering exemptions under Regulation A and Regulation D of the Securities Act of 1933, as amended, as a result of the Settlement Order.
Certain of the Forward-Looking Statements contained herein concerning the industries in which we conduct our business are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of these industries, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors, which are described further below.

The Forward-Looking Statements contained herein are based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including: (i) our ability to effectively navigate developments related to the Anti-Dumping Investigation and the proposed anti-dumping duty to which the Company’s imports would be subject and its impact on our operations in Israel; (ii) our ability to effectively navigate developments related to the Middle East Conflict and its impact on our employees and operations in Israel, the supply of product in the market and demand for product by medical patients in Israel; (iii) our ability to efficiently and effectively distribute our PEACE NATURALS® brand in markets outside of Canada and Israel; (iv) expectations related to the impact of our decision to exit our U.S. hemp-derived cannabinoid product operations; (v) our ability to realize the expected cost-savings, efficiencies and other benefits of our Realignment and other announced cost-cutting measures and employee turnover related thereto; (vi) our ability to efficiently and effectively manage our operations at our Peace Naturals Campus; (vii) our ability to efficiently and effectively acquire raw materials on a timely and cost-effective basis from third parties or Cronos GrowCo; (viii) our ability to realize the expected benefits related to the expansion of Cronos GrowCo’s purpose-built cannabis facility (including the quantity and quality of any additional supply provided thereby and the stability of pricing and demand with respect to such supply) and the ability of Cronos GrowCo to repay the credit facility provided by Cronos; (ix) High Tide’s ability to repay the High Tide Loan, the performance of the High Tide Loan and the High Tide Warrant, and our ability to realize benefits related to the performance of the High Tide Warrant; (x) our ability to complete the acquisition of CanAdelaar on the terms and within the timelines anticipated, including the timely receipt of required regulatory approvals and the satisfaction of other closing conditions, and our ability to realize any expected benefits, synergies and operational performance associated with such acquisition; (xi) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our business combinations and strategic investments; (xii) the production and manufacturing capabilities and output from our facilities and our joint ventures, strategic alliances and equity investments; (xiii) government regulation of our activities and products including, but not limited to, the areas of cannabis taxation and environmental protection; (xiv) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (xv) consumer interest in and the scalability of our products; (xvi) our ability to differentiate our products, including through the utilization of rare cannabinoids; (xvii) competition; (xviii) anticipated and unanticipated costs; (xix) our ability to generate cash flow from operations; (xx) our ability to conduct operations in a safe, efficient and effective manner; (xxi) our ability to hire and retain qualified staff and acquire equipment and services in a timely and cost-efficient manner; (xxii) our ability to complete planned dispositions and, if completed, obtain our anticipated sales price; (xxiii) general economic, financial market, regulatory and political conditions in which we operate; (xxiv) management’s perceptions of historical trends, current conditions and expected future developments; and (xxv) other considerations that management believes to be appropriate in the circumstances. While our management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.

By their nature, Forward-Looking Statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the Forward-Looking Statements in this press release and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Such factors include, without limitation, negative impacts on our business and operations in Israel due to the Anti-Dumping Investigation, including that we may not be able to produce, import or sell our products in Israel as a result thereof; negative impacts on our employees, business and operations in Israel due to the Middle East Conflict, including that we may not be able to produce, import or sell our products or protect our people or facilities in Israel during the Middle East Conflict, the supply of product in the market and the demand for product by medical patients in Israel, and inflationary pressures and related increases in input, production, transportation and other operating costs, as well as potential impacts on consumer purchasing power; that we may not be able to successfully maintain or expand distribution of our products in our markets outside of Canada or Israel or generate meaningful revenue in those markets; that we may be unable to further streamline our operations and expenses; that we may not be able to effectively and efficiently re-enter the U.S. market in the future; that we may not be able to access raw materials on a timely and cost-effective basis from third parties or Cronos GrowCo; that the expected benefits of the expansion of Cronos GrowCo’s purpose-built cannabis facility (including any additional supply provided thereby) may not be fully realized within a reasonable time or at all or that Cronos GrowCo may not be able to repay its borrowings under the credit facility provided by Cronos; that the expected benefits of the High Tide Warrant and the High Tide Loan may not be fully realized within a reasonable time or at all or that High Tide may not be able to repay its borrowings under the High Tide Loan; that we may not be able to consummate our planned acquisition of CanAdelaar on the anticipated timeline or at all; the military conflict between Russia and Ukraine may disrupt our operations and those of our suppliers and distribution channels and negatively impact the demand for and use of our products; the risk that cost savings and any other synergies from the Altria Investment may not be fully realized or may take longer to realize than expected; failure to execute key personnel changes; that our Realignment and our further leveraging of our strategic partnerships will not result in the expected cost-savings, efficiencies and other benefits or will result in greater than anticipated turnover in personnel; that we may not be able to efficiently and effectively manage our operations, and any changes thereto, at our Peace Naturals Campus; lower levels of revenues; the lack of consumer demand for or our inability or challenges in successfully scaling our products; our inability to manage disruptions in credit markets; unanticipated future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; failure to realize expected growth opportunities; the lack of cash flow necessary to execute our business plan (either within the expected timeframe or at all); difficulty raising capital; the potential adverse effects of judicial, regulatory or other proceedings, or threatened litigation or proceedings, on our business, financial condition, results of operations and cash flows; volatility in and/or degradation of general economic, market, industry or business conditions; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis and U.S. hemp products in vaping devices; the unexpected effects of actions of third parties such as competitors, activist investors or federal (including U.S. federal), state, provincial, territorial or local regulatory authorities or self-regulatory organizations; adverse changes in regulatory requirements in relation to our business and products; our failure to improve our internal control environment and our systems, processes and procedures; and the factors discussed under Part I, Item 1A “Risk Factors” of the Annual Report on Form 10-K for the year ended December 31, 2025 and under Part II, Item 1A “Risk Factors” in our Quarterly Reports. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on Forward-Looking Statements.

Forward-Looking Statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as of and for periods ended on certain dates and to present information about management’s current expectations and plans relating to the future, and the reader is cautioned not to place undue reliance on these Forward-Looking Statements because of their inherent uncertainty and to appreciate the limited purposes for which they are being used by management. While we believe that the assumptions and expectations reflected in the Forward-Looking Statements are reasonable based on information currently available to management, there is no assurance that such assumptions and expectations will prove to have been correct. Forward-Looking Statements are made as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. We undertake no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such Forward-Looking Statements. The Forward-Looking Statements contained in this press release and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf are expressly qualified in their entirety by these cautionary statements.

As used in this press release, “CBD” means cannabidiol and “U.S. hemp” has the meaning given to the term “hemp” in the U.S. Agricultural Improvement Act of 2018, including hemp-derived CBD.

Cronos Group Inc.
Condensed Consolidated Balance Sheets
(In thousands of U.S. dollars, except share amounts, unaudited)
     As of
March 31,
2026 As of
December 31,
2025Assets   Current assets   Cash and cash equivalents$821,856  $791,794 Short-term investments —   40,000 Accounts receivable, net 32,962   34,099 Interest receivable 5,734   8,654 Other receivables 13,546   14,445 Current portion of loans receivable, net 128   — Inventory, net 48,676   46,750 Prepaids and other current assets 4,974   8,344 Total current assets 927,876   944,086 Other investments 5,199   7,664 Non-current portion of loans receivable, net 20,803   20,847 Property, plant and equipment, net 142,102   145,865 Right-of-use assets 1,303   1,422 Goodwill 65,436   66,478 Intangible assets, net 8,549   8,890 Deferred tax assets 841   1,888 Total assets$1,172,109  $1,197,140 Liabilities   Current liabilities   Accounts payable$10,281  $11,640 Income taxes payable 1,369   — Accrued liabilities 30,601   36,210 Current portion of lease obligation 169   337 Total current liabilities 42,420   48,187 Non-current portion due to non-controlling interests 749   733 Non-current portion of lease obligation 1,142   1,172 Deferred tax liabilities 3,984   4,089 Total liabilities 48,295   54,181 Shareholders’ equity   Share capital and additional paid-in capital (no par value; authorized for issue as of March 31, 2026 and December 31, 2025: unlimited; shares outstanding as of March 31, 2026 and December 31, 2025: 376,258,707 and 381,592,969, respectively) 647,040   662,983 Retained earnings 460,540   447,756 Accumulated other comprehensive loss (33,918)  (16,842)Total equity attributable to shareholders of Cronos Group 1,073,662   1,093,897 Non-controlling interests 50,152   49,062 Total shareholders’ equity 1,123,814   1,142,959 Total liabilities and shareholders’ equity$1,172,109  $1,197,140  Cronos Group Inc.
Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
    Three months ended March 31,(In thousands of U.S. dollars, except share and per share amounts, unaudited) 2026   2025 Net revenue, before excise taxes$58,965  $41,898 Excise taxes (13,755)  (9,636)Net revenue 45,210   32,262 Cost of sales 25,392   18,528 Inventory write-down 665   — Gross profit 19,153   13,734 Operating expenses   Sales and marketing 5,615   4,565 Research and development 1,413   793 General and administrative 11,736   9,309 Restructuring costs 484   555 Share-based compensation 1,313   2,088 Depreciation and amortization 425   496 Total operating expenses 20,986   17,806 Operating loss (1,833)  (4,072)Other income (expense)   Interest income, net 8,853   9,665 Gain (loss) on revaluation of financial instruments (2,484)  49 Foreign currency gain 13,699   1,583 Change in allowance for credit loss on non-operating loan (106)  — Other, net 10   43 Total other income 19,972   11,340 Income before income taxes 18,139   7,268 Income tax provision (benefit) 2,428   (455)Net income 15,711   7,723 Net income attributable to non-controlling interest 1,959   1,601 Net income attributable to Cronos Group$13,752  $6,122     Comprehensive income (loss)   Net income$15,711  $7,723 Other comprehensive loss   Foreign exchange loss on translation (17,945)  (3,082)Comprehensive income (loss) (2,234)  4,641 Comprehensive income attributable to non-controlling interests 1,090   1,443 Comprehensive income (loss) attributable to Cronos Group$(3,324) $3,198     Net income per share   Basic net income per share attributable to Cronos Group$0.04  $0.02 Diluted net income per share attributable to Cronos Group$0.04  $0.02  Cronos Group Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands of U.S. dollars, except share amounts, unaudited)
  Three months ended March 31,  2026   2025 Operating activities   Net income$15,711  $7,723 Adjustments to reconcile net income to net cash used in operating activities:   Share-based compensation 1,313   2,088 Depreciation and amortization 3,727   2,840 Loss from investments 2,484   68 Changes in expected credit losses on long-term financial assets 107   9 Inventory step-up recorded to cost of sales —   517 Foreign currency gain (13,699)  (1,583)Other non-cash operating activities, net 979   779 Changes in operating assets and liabilities:   Accounts receivable, net 879   (3,409)Interest receivable 2,360   3,453 Other receivables 724   (2,379)Prepaids and other current assets 3,310   (60)Inventory, net (2,039)  (1,631)Accounts payable (1,206)  (1,637)Income taxes payable 1,387   4 Accrued liabilities (5,139)  (8,878)Net cash provided by (used in) operating activities 10,898   (2,096)Investing activities   Purchase of short-term investments —   (40,000)Proceeds from short-term investments 40,000   — Purchase of property, plant and equipment (1,875)  (15,258)Purchase of intangible assets (96)  (98)Net cash provided by (used in) investing activities 38,029   (55,356)Financing activities   Repurchases of common stock (16,730)  — Withholding taxes paid on share-based awards (1,538)  (2,930)Net cash used in financing activities (18,268)  (2,930)Effect of foreign currency translation on cash and cash equivalents (597)  (604)Net change in cash and cash equivalents 30,062   (60,986)Cash and cash equivalents, beginning of period 791,794   858,805 Cash and cash equivalents, end of period$821,856  $797,819 Supplemental cash flow information   Interest paid$—  $— Interest received$9,370  $13,052 Income taxes paid$8  $50          Non-GAAP Measures

Cronos reports its financial results in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”). This press release refers to measures not recognized under U.S. GAAP (“non-GAAP measures”). These non-GAAP measures do not have a standardized meaning prescribed by U.S. GAAP and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these non-GAAP measures are provided as a supplement to corresponding U.S. GAAP measures to provide additional information regarding the results of operations from management’s perspective. Accordingly, non-GAAP measures should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. All non-GAAP measures presented in this press release are reconciled to their closest reported U.S. GAAP measure. Reconciliations of historical adjusted financial measures to corresponding U.S. GAAP measures are provided below.

Adjusted EBITDA

Management reviews Adjusted EBITDA, a non-GAAP measure, which excludes non-cash items and items that do not reflect management’s assessment of ongoing business performance. Management defines Adjusted EBITDA as net income (loss) before interest, tax expense (benefit), depreciation and amortization adjusted for: share of (income) loss from equity method investments; impairment loss on goodwill and intangible assets; impairment loss on long-lived assets; (gain) loss on revaluation of derivative liabilities; (gain) loss on revaluation of financial instruments; gain on revaluation of loan receivable; gain on revaluation of equity method investment; transaction costs related to strategic projects; loss on held-for-sale assets; impairment loss on other investments; foreign currency transaction (gain) loss; other, net; loss from discontinued operations; change in allowance for credit loss on non-operating loan; restructuring costs; inventory write-downs resulting from restructuring actions; share-based compensation; costs related to the Israel Ministry of Economy and Industry dumping inquiry; purchase accounting adjustment-related inventory step-up adjustments recorded through cost of sales; and restatement litigation costs and reserves related to the restatements of our 2019 and 2021 interim financial statements (the “Restatements”), including the costs related to the settlement of the SEC’s and the OSC’s investigations of the Restatements and legal costs of defending shareholder class action complaints brought against us as a result of the 2019 restatement (see Note 10(b) “Contingencies,” to the condensed consolidated financial statements under Item 1 of our Quarterly Report for a discussion of the shareholder class action complaints relating to the restatement of the 2019 interim financial statements and the settlement of the SEC’s and the OSC’s investigations of the Restatements). Results are reported as total consolidated results, reflecting our reporting structure of one reportable segment.

Management believes that Adjusted EBITDA provides useful insight into underlying business trends and results and facilitates comparison of period-over-period results. Management uses Adjusted EBITDA for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets.

Beginning in 2025, the Company modified the composition of Adjusted EBITDA to exclude the impact of the provision for expected credit losses recognized under ASC 326 solely with respect to the High Tide Loan (see Note 4 “Loans Receivable, net” to the condensed consolidated financial statements under Item 1 of our Quarterly Report for further information). Management determined that excluding this non-cash provision provides investors with additional insight into period-over-period operating performance by isolating credit-risk movements unrelated to the Company’s core operations.

Management believes that this change provides additional information regarding the Company’s ongoing operational results and enhances comparability with peers that do not routinely extend credit to third parties. This change does not affect the Company’s GAAP financial statements.

The following tables set forth a reconciliation of Net income as determined in accordance with U.S. GAAP to Adjusted EBITDA for the periods indicated:

 Three months ended March 31, 2026Net income$15,711 Interest income, net (8,853)Income tax provision 2,428 Depreciation and amortization 3,727 EBITDA 13,013 Loss on revaluation of financial instruments(i) 2,484 Foreign currency transaction gain (13,699)Transaction costs(ii) 959 Other, net(iii) (10)Restructuring costs(iv) 484 Share-based compensation(v) 1,313 Restatement litigation costs(vi) 411 Israel Ministry of Economy and Industry dumping inquiry expense(vii) 18 Change in allowance for credit loss on non-operating loan(viii) 106 Adjusted EBITDA$5,079   Three months ended March 31, 2025Net income$7,723 Interest income, net (9,665)Income tax benefit (455)Depreciation and amortization 2,840 EBITDA 443 Gain on revaluation of financial instruments(i) (49)Foreign currency transaction gain (1,583)Transaction costs(ii) 40 Other, net(iii) (43)Restructuring costs(iv) 555 Share-based compensation(v) 2,088 Restatement litigation costs(vi) 47 Israel Ministry of Economy and Industry dumping inquiry expense(vii) 274 Inventory step-up recorded to cost of sales(ix) 517 Adjusted EBITDA$2,289  (i)     For the three months ended March 31, 2026, the loss on revaluation of financial instruments was driven by a loss related to the Company’s High Tide Warrant and the Company’s equity securities in Vitura. For the three months ended March 31, 2025, the gain on revaluation of financial instruments related primarily to the revaluation of the Company’s DSU liability, partially offset by a loss on the Company’s equity securities in Vitura.

(ii)     For the three months ended March 31, 2026, transaction costs represented fees related to the pending acquisition of CanAdelaar. For the three months ended March 31, 2025, transaction costs represented legal, financial and other advisory fees and expenses incurred in connection with the Cronos GrowCo Transaction. These costs are included in general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss).

(iii)     For the three months ended March 31, 2026, other, net related to rental income. For the three months ended March 31, 2025, other, net related to (gain) loss on disposal of assets and (gain) loss on revaluation of derivative liabilities.

(iv)     For the three months ended March 31, 2026 and 2025, restructuring costs related to employee-related severance costs and IT infrastructure and finance transformation costs associated with the Realignment.

(v)     For the three months ended March 31, 2026, share-based compensation related to the expenses of share-based compensation awarded to employees and DSUs issued to our Board of Directors, each under the Company’s share-based award plans. For the three months ended March 31, 2025, share-based compensation related to the expenses of share-based compensation awarded to employees, each under the Company’s share-based award plans.

(vi)     For the three months ended March 31, 2026 and 2025, restatement litigation costs included legal costs incurred defending shareholder class action complaints brought against the Company as a result of the 2019 restatement.

(vii)     For the three months ended March 31, 2026 and 2025, Israel Ministry of Economy and Industry dumping inquiry expense included expenditures relating to the regulatory inquiry about alleged dumping of medical cannabis products in Israel and related litigation and external relations expenses.

(viii)     For the three months ended March 31, 2026, change in allowance for credit loss on non-operating loan represents the allowance recognized on the High Tide loan receivable.

(ix)     For the three months ended March 31, 2025, inventory step-up recorded to cost of sales represents the portion of the inventory step-up from the Cronos GrowCo Transaction that was recorded through the condensed consolidated statements of net income (loss) and comprehensive income (loss).

For the three months ended March 31, 2026, Adjusted EBITDA was $5.1 million, representing an improvement of $2.8 million from the three months ended March 31, 2025. The improvement was primarily due to higher gross profit, partially offset by higher operating expenses due to higher sales and marketing, general and administrative, and research and development costs.

Adjusted Gross Profit and Adjusted Gross Margin

To supplement the consolidated financial statements presented in accordance with U.S. GAAP, we have presented Adjusted Gross Profit and Adjusted Gross Margin, non-GAAP measures that exclude the impacts of inventory-related purchase accounting adjustments from the calculations of gross profit and gross margin, which resulted from the Cronos GrowCo Transaction. Results are reported as total consolidated results, reflecting our reporting structure of one reportable segment.

Management believes that Adjusted Gross Profit and Adjusted Gross Margin provide useful insight into underlying business trends to facilitate comparisons of period-over-period results by removing the impacts of inventory-related purchase accounting adjustments resulting from the Cronos GrowCo Transaction, which reflect a one-time event and do not reflect management’s assessment of ongoing business performance.

The following table sets forth a reconciliation of Gross profit and Gross margin, each as determined in accordance with U.S. GAAP, to Adjusted Gross Profit and Adjusted Gross Margin, respectively, for the periods indicated:

(in thousands of USD)Three months ended March 31, Change  2026   2025  $ %Net revenue$45,210  $32,262  $12,948  40%        Gross profit$19,153  $13,734  $5,419  39%Inventory step-up recorded to cost of sales —   517   (517) N/AAdjusted Gross Profit$19,153  $14,251  $4,902  34%        Gross margin(i) 42%  43% N/A (1)ppAdjusted Gross Margin(ii) 42%  44% N/A (2)pp (i)     Gross margin is defined as gross profit divided by net revenue.

(ii)     Adjusted Gross Margin is defined as Adjusted Gross Profit divided by net revenue.

For the three months ended March 31, 2026, Adjusted Gross Profit was $19.2 million, representing an increase of $4.9 million from the three months ended March 31, 2025. The increase was primarily due to higher average sales prices, largely driven by a mix shift to Israel and other countries, which carry no excise taxes, and higher sales volumes.

Constant Currency

To supplement the consolidated financial statements presented in accordance with U.S. GAAP, we have presented constant currency adjusted financial measures for net revenue, gross profit, gross profit margin, operating expenses, net income (loss) and Adjusted EBITDA for the three months ended March 31, 2026, as well as cash and cash equivalents and short-term investment balances as of March 31, 2026 compared to December 31, 2025, which are considered non-GAAP financial measures. We present constant currency information to provide a framework for assessing how our underlying operations performed excluding the effect of foreign currency rate fluctuations. To present this information, current and comparative prior period income statement results in currencies other than U.S. dollars are converted into U.S. dollars using the average exchange rates from the three month comparative period in 2025 rather than the actual average exchange rates in effect during the respective current period; constant currency current and prior comparative balance sheet information is translated at the prior year-end spot rate rather than the current period spot rate. All growth comparisons relate to the corresponding period in 2025. We have provided this non-GAAP financial information to aid investors in better understanding the performance of our operations. The non-GAAP financial measures presented in this press release should not be considered as a substitute for, or superior to, the measures of financial performance prepared in accordance with U.S. GAAP.

The table below sets forth certain measures of consolidated results from continuing operations on a constant currency basis for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 as well as cash and cash equivalents and short-term investments as of March 31, 2026 and December 31, 2025, both on an as-reported and constant currency basis (in thousands):

 As Reported As Adjusted for Constant Currency Three months ended March 31, As Reported Change Three months ended March 31, Constant Currency Change  2026   2025  $ %  2026  $ %Net revenue$45,210  $32,262  $12,948  40% $41,913  $9,651  30%Gross profit 19,153   13,734   5,419  39%  17,588   3,854  28%Gross margin 42%  43% N/A (1)pp  42% N/A (1)pp              Operating expenses 20,986   17,806   3,180  18%  20,005   2,199  12%Net income 15,711   7,723   7,988  103%  14,809   7,086  92%Adjusted EBITDA$5,079  $2,289  $2,790  122% $4,153  $1,864  81%               As of March 31, As of December 31, As Reported Change As of March 31, Constant Currency Change  2026   2025  $ %  2026  $ %Cash and cash equivalents$821,856  $791,794  $30,062  4% $822,316  $30,522  4%Short-term investments —   40,000   (40,000) N/A  —   (40,000) N/ATotal cash and cash equivalents and short-term investments$821,856  $831,794  $(9,938) (1)% $822,316  $(9,478) (1)%                           Net revenue

 As Reported As Adjusted for Constant Currency Three months ended March 31, As Reported Change Three months ended March 31, Constant Currency Change 2026
 2025
 $ % 2026
 $ %Cannabis flower$33,734 $23,344 $10,390  45% $30,972 $7,628  33%Cannabis extracts 11,457  8,608  2,849  33%  10,923  2,315  27%Other 19  310  (291) (94)%  18  (292) (94)%Net revenue$45,210 $32,262 $12,948  40% $41,913 $9,651  30%  As Reported As Adjusted for Constant Currency Three months ended March 31, As Reported Change Three months ended March 31, Constant Currency Change 2026
 2025
 $ % 2026
 $ %Canada$25,351 $20,130 $5,221 26% $24,221 $4,091 20%Israel 14,151  9,229  4,922 53%  12,240  3,011 33%Other countries 5,708  2,903  2,805 97%  5,452  2,549 88%Net revenue$45,210 $32,262 $12,948 40% $41,913 $9,651 30%                      For the three months ended March 31, 2026, net revenue on a constant currency basis was $41.9 million, representing a 30% increase from the three months ended March 31, 2025. On a constant currency basis, net revenue increased for the three months ended March 31, 2026, primarily due to higher cannabis flower sales in Israel and other countries, which carry no excise taxes, and higher cannabis extract and flower sales in the Canadian market.

Gross profit

For the three months ended March 31, 2026, gross profit on a constant currency basis was $17.6 million, representing a 28% increase from the three months ended March 31, 2025. On a constant currency basis, gross profit increased for the three months ended March 31, 2026, primarily due to higher average sales prices, largely driven by a mix shift to Israel and other countries, which carry no excise taxes, and higher sales volumes. For the three months ended March 31, 2025, we recognized $0.5 million of inventory step-up from the Cronos GrowCo Transaction in cost of sales. No such costs were recognized for the three months ended March 31, 2026.

Operating expenses

For the three months ended March 31, 2026, operating expenses on a constant currency basis were $20.0 million, representing a 12% increase from the three months ended March 31, 2025. On a constant currency basis, operating expenses increased for the three months ended March 31, 2026, primarily due to higher salaries and benefits, transaction costs and product development costs, partially offset by lower share-based compensation expense.

Net income

For the three months ended March 31, 2026, net income on a constant currency basis was $14.8 million, representing a higher net income of $7.1 million from the three months ended March 31, 2025. On a constant currency basis, the improvement in net income for the three months ended March 31, 2026, was primarily due to higher gross profit and other income, partially offset by higher operating expenses.

Adjusted EBITDA

For the three months ended March 31, 2026, Adjusted EBITDA on a constant currency basis was $4.2 million, representing a $1.9 million improvement from the three months ended March 31, 2025. The improvement in Adjusted EBITDA for the three months ended March 31, 2026 on a constant currency basis was driven by higher gross profit, partially offset by higher operating expenses due to higher sales and marketing, general and administrative, and research and development costs.

Cash and cash equivalents & short-term investments

Cash and cash equivalents and short-term investments on a constant currency basis decreased 1% to $822.3 million as of March 31, 2026, from $831.8 million as of December 31, 2025. The decrease in cash and cash equivalents and short-term investments on a constant currency basis is primarily due to repurchases of common stock, purchases of property, plant and equipment, and withholding taxes paid on share-based awards, partially offset by positive cash from operating activities.

Foreign currency exchange rates

All currency amounts in this press release are stated in U.S. dollars, which is our reporting currency, unless otherwise noted. All references to “dollars” or “$” are to U.S. dollars. The assets and liabilities of our foreign operations are translated into dollars at the exchange rate in effect as of March 31, 2026, March 31, 2025, and December 31, 2025. Transactions affecting the shareholders’ equity (deficit) are translated at historical foreign exchange rates. The condensed consolidated statements of net income (loss) and comprehensive income (loss) and condensed consolidated statements of cash flows of our foreign operations are translated into dollars by applying the average foreign exchange rate in effect for the reporting period as reported on Bloomberg.

The exchange rates used to translate from Canadian dollars (“C$”) to dollars are shown below:

(Exchange rates are shown as C$ per $)As of March 31,
2026 March 31,
2025 December 31,
2025Spot rate1.3916 1.4393 1.3698Year-to-date average rate1.3720 1.4356 N/A       The exchange rates used to translate from Israeli New Shekels (“ILS”) to dollars are shown below:

(Exchange rates are shown as ILS per $)As of March 31,
2026 March 31,
2025 December 31,
2025Spot rate3.1441 3.7191 3.1863Year-to-date average rate3.1240 3.6145 N/A       For further information, please contact:
Harrison Aaron
Investor Relations
Tel: (416) 504-0004
[email protected]

1 Hifyre Retail Analytics - National Retail Dollar by Brand in Canada - Q1 2026.
2 Market share and ranking information from pharmacy data collected by Cronos - Q1 2026.
3 Hifyre Retail Analytics - National Retail Dollar by Brand in Canada - Q1 2026.
4 Market share and ranking information from pharmacy data collected by Cronos - Q1 2026.
5 Hifyre Retail Analytics - National Retail Dollar by Brand in Canada - Q1 2026.

MarketBeat Instant News Alerts

2 hours ago

Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of StockMarketBeat

MarketAxess Holdings Inc. (NASDAQ:MKTX - Get Free Report) General Counsel Scott Pintoff sold 100 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $116.03, for a total transaction of $11,603.00. Following the transaction, the general counsel owned 11,786 shares in the company, valued at approximately $1,367,529.58. The trade was a 0.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:MKTX

Read Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of Stock

Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 327

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

Cronos Group Inc. reported Q1 '26 revenue up 40% to $45 million, exceeding estimates. Despite strong top-line growth, CRON posted a small operating loss of $1.8 million, with net income driven by interest and FX gains. CapEx dropped sharply by 87% year-over-year to $1.9 million, reflecting tighter capital discipline.

These 3 Marijuana Stocks Are The Future Of The Industry

3 minute read Here Are The Ways These Marijuana Stocks Will Help You Make Money Many marijuana stock investors have a strong positive outlook on the future of the market. If you’ve been watching the cannabis sector, then you know how volatile and uncertain trading can be. Yet there have been changes that give more upside to what the future of investing can hold. As cannabis is now a class 3 substance federally, more companies are making shifts in their business to get in line with this new legislation.

Cannabis companies will now be able to receive certain breaks and other benefits for their businesses. This has led to seeing an influx of momentum and a buildup. The cannabis industry is still fairly new, and having better laws in place can help determine how the market reacts. Especially if it benefits the company and investors at the same time.

At this time, the way companies are running and operating is showing people that more change is happening, and it is paving the way for the future. Legal cannabis is globally becoming more widely accepted both medically and recreationally. It is being treated no differently than alcohol or tobacco these days, and it further grows with daily social acceptance. Below are several marijuana stocks to watch for better trading in 2026.

The Best Canadian Marijuana Stocks For Investors Cronos Group Inc. (OTC:CRON) Aurora Cannabis Inc.(OTC:ACB) SNDL Inc.(NASDAQ:SNDL) Cronos Group Inc. Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. On May 11th 2026, the company reported its Q1 2026 earnings.

Q1 2026 Highlights Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada Ninth consecutive quarter of record net revenue in Israel, where PEACE NATURALS® continues to be the number one cannabis brand2 [Read More] Here Are Some Ways Marijuana Stocks Can Make You A Profit

Aurora Cannabis Inc. Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. In recent updates, the company announced it has been granted Plant Breeders’ Rights in Canada.

Specifically for two proprietary cannabis cultivars developed through its world-class breeding program. This certification gives Aurora the exclusive rights to grow, propagate, and sell finished products produced from these varieties.

[Read More] Cannabis REITs Gaining Momentum in 2026: 3 Stocks to Watch

SNDL Inc. SNDL Inc. engages in the production, distribution, and sale of cannabis products for the adult-use market in Canada and internationally. 

The most recent company update is the reporting of its Q1 2026 financial and operational results.

Q1 2026 Financial Highlights And Key Mentions Net revenue for the first quarter of 2026 was $195.9 million. Gross profit of $52.8 million for the first quarter of 2026 represents a decline of $(3.8) million. Gross margin (1) of 27.0% in the first quarter of 2026 represents a reduction of -0.7%. Operating Loss of $(9.1) million for the first quarter of 2026, representing an improvement of $2.9 million. Cash flow was negative by $(26.7) million in the first quarter of 2026, partly driven by cash outflows of $9.6 million. MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]

Spinach® vapes, known for exceptional quality, bold flavor profiles and advanced hardware, continue to resonate with adult consumers across Canada June 11, 2026 07:30 ET  | Source: Cronos Group Inc.

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, today announced that its Spinach® vape portfolio has become the top‑selling vape brand in Canada, capturing 10.4%1 market share of the total vapes category in April 2026, a position that Cronos has held since January 2026.

Since entering the vape category, the Spinach® brand has built a best‑in‑class offering rooted in quality, flavor, and technology. Spinach® vapes are crafted using high‑purity extracts, feature vibrant and distinctive terpene profiles, and utilize advanced hardware designed to deliver smooth, reliable performance for adult consumers.

“Spinach® vapes were created to bring high-quality, flavorful, and consistent experiences to adult consumers. Reaching the #1 position in Canada marks an incredible milestone,” said Jeff Jacobson, Chief Growth Officer, Cronos. “We’re grateful to our consumers for their loyalty and passion for the brand. This achievement motivates us to keep raising the bar with innovative formulations, differentiated flavor profiles and leading-edge hardware across our vape lineup.”

“Our strategy is centered on developing disruptive, borderless products that can scale as regulations evolve globally,” said Mike Gorenstein, Chairman, President and CEO, Cronos. “Reaching #1 market share in the Canadian vape category1 validates our product innovation engine and strengthens our confidence as we continue expanding our platform of cannabinoid products around the world.”

This summer, the Spinach® brand will launch several new SKUs across its vape portfolio, including three new flavors for the Spinach PUFFERZ™ all-in-one 1g vape and its first-ever limited-time offer (LTO) vape, all infused with liquid diamonds for bigger and smoother hits.

The newest flavors are:

Spinach PUFFERZ™ Strawberry Burst (Sativa)Spinach PUFFERZ™ Peach Iced Tea (Sativa)Spinach PUFFERZ™ Grape Gas (Hybrid)Spinach® Orange Vanilla Twist 1g vape (Sativa), the brand’s first LTO vape for the summer season, available in a 510-threaded cartridge. The new Spinach PUFFERZ™ flavors and the LTO Spinach® Orange Vanilla Twist 1g vape will be available in Alberta and Ontario in late June, with national availability later this summer.

The full lineup of Spinach® vapes, available in a range of popular flavors, formats, and cannabinoid ratios, can be viewed at: https://spinachcannabis.com/forms/vape/. For more information and availability on all Spinach® products, please visit: https://spinachcannabis.com/.

1 HiFyre Retail Analytics – National Vape Retail Dollar Sales by Brand in Canada – January – April 2026.

About Cronos
Cronos is an innovative global cannabis company focused on scaling leading consumer goods products through R&D and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT®, and Lord Jones®. For more information about Cronos and its brands, please visit: https://thecronosgroup.com/.

Forward-looking Statements
This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about continued product innovations, strategies with respect to the development of scalable cannabinoid products, expansion into new and existing markets, the Company’s product innovation engine, the evolution of cannabis regulations globally and the Company’s ability to adapt and scale accordingly, expectations of continued consumer demand, brand strength and market performance of Spinach® products, future product launches and rollout timing for new Spinach® vape SKUs, anticipated product availability in Ontario and national availability timing, and the Company’s intention to build an international iconic brand portfolio by scaling leading consumer goods products through R&D and innovation. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, each of which have been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

For further information, please contact:

Media Relations Contact:
Emily Whalen
Communications
Tel: (416) 504-0004
[email protected]

Investor Relations Contact:
Harrison Aaron
Investor Relations
Tel: (416) 504-0004
[email protected]